Hydrazone compound and electrophotographic photoreceptor and organic electroluminescent element both containing the same
    44.
    发明公开
    Hydrazone compound and electrophotographic photoreceptor and organic electroluminescent element both containing the same 失效
    Hydrazonverbindung und diese enthaltende电子照相机Photorezeptor und organisches elektrolumineszentes元素。

    公开(公告)号:EP0658815A1

    公开(公告)日:1995-06-21

    申请号:EP94119757.6

    申请日:1994-12-14

    摘要: There are provided a hydrazone compound represented by formula (I), an electrophotographic photoreceptor which has a photosensitive layer containing the compound on an electrically conductive support, and an organic electroluminescent element containing the compound as a charge transporting material:

    wherein Ar₁ represents a substituted or unsubstituted phenylene group, a substitued or unsubstituted naphthylene group, a substitued or unsubstituted biphenylene group, or a substituted or unsubstituted anthrylene group, Ar₂ represents a substituted or unsubstituted aryl group, R₁ and R₂ each independently represents a hydrogen atom, a halogen atom, an unsubstituted alkyl group, or an unsubstituted alkoxy group, R₃ represents an unsubstituted alkyl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted aryl group, Z represents an ethylene group or a vinylene group, and n is 0 or 1.

    摘要翻译: 提供由式(I)表示的腙化合物,在导电载体上具有含有化合物的感光层的电子照相感光体和含有作为电荷输送材料的化合物的有机电致发光元件:其中Ar 1表示 取代或未取代的亚苯基,取代或未取代的亚萘基,取代或未取代的亚联苯基或取代或未取代的亚蒽基,Ar 2表示取代或未取代的芳基,R 1和R 2各自独立地表示氢原子,卤素 原子,未取代的烷基或未取代的烷氧基,R3表示未取代的烷基,取代或未取代的芳烷基或取代或未取代的芳基,Z表示亚乙基或亚乙烯基,n表示0或 1。

    COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
    49.
    发明公开
    COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS 审中-公开
    组合物和方法用于治疗神经系统疾病

    公开(公告)号:EP2847169A1

    公开(公告)日:2015-03-18

    申请号:EP13787695.9

    申请日:2013-01-28

    发明人: KANDULA. Mahesh

    摘要: The invention relates to the compounds of formula I and formula IA or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I and formula IA; and methods for treating or preventing neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of epilepsy, bipolar disorder, trigeminal neuralgia, attention-deficit hyperactivity disorder (ADHD), schizophrenia, neuropathic pain, seizures, bipolar disorder, mania, phantom limb syndrome, complex regional pain syndrome, paroxysmal extreme pain disorder, neuromyotonia, intermittent explosive disorder, borderline personality disorder, Myotonia congenita and post-traumatic stress disorder.